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Abstract
Background: Primary care organisations are faced with implementing a large number of guideline
recommendations. We present methods by which the number of eligible patients requiring
treatment, and the relative benefits to the whole population served by a general practice or Primary
Care Trust, can be calculated to help prioritise between different guideline recommendations.
Methods: We have developed measures of population impact, "Number to be Treated in your
Population (NTP)" and "Number of Events Prevented in your Population (NEPP)". Using literature-
based estimates, we have applied these measures to guidelines for pharmacological methods of
secondary prevention of myocardial infarction (MI) for a hypothetical general practice population
of 10,000.
Results: Implementation of the NICE guidelines for the secondary prevention of MI will require
176 patients to be treated with aspirin, 147 patients with beta-blockers and with ACE-Inhibitors
and 157 patients with statins (NTP). The benefit expressed as NEPP will range from 1.91 to 2.96
deaths prevented per year for aspirin and statins respectively. The drug cost per year varies from
€1940 for aspirin to €60,525 for statins. Assuming incremental changes only (for those not already
on treatment), aspirin post MI will be added for 37 patients and produce 0.40 of a death prevented
per year at a drug cost of €410 and statins will be added for 120 patients and prevent 2.26 deaths
per year at a drug cost of €46,150. An appropriate policy might be to reserve the use of statins
until eligible patients have been established on aspirin, ACE-Inhibitors and beta blockers.
Conclusions: The use of population impact measures could help the Primary Care Organisation
to prioritise resource allocation, although the results will vary according to local conditions which
should be taken into account before the measures are used in practice.
Background
Primary care organisations are faced with implementing a
large number of guideline recommendations. Methods to
facilitate assessing their population health benefit and
costs are needed for organisations to prioritise between
different recommendations. We have used previous work
on creating measures of the population impact of inter-
ventions as a basis for the development of new measures
that can relate to a general practice population or Primary
Care Trust (PCT). We have taken as an example the UK
National Institute for Clinical Excellence (NICE) guide-
lines on secondary prevention for patients who have
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experienced a myocardial infarction (MI), including those
who now have heart failure [1].
The guidelines recommend aspirin, ACE-inhibitor (ACE-
I), beta blockers (BB) and statins for MI, and ACE-I, BB
and spironolactone for heart failure.
We present data to illustrate the methods by which the
number of eligible patients requiring treatment and the
relative benefits to an individual practice or Primary Care
Trust (PCT) of the introduction of these guidelines can be
calculated. We have used a base population of 10,000
people which can be adjusted up (for a PCT) or down (for
a smaller practice) as appropriate.
Methods
We have examined the literature to estimate the propor-
tion of a typical practice population who are aged 50 years
or more (which would include the majority of those to
whom the guidelines refer), the proportion of the popula-
tion within these age groups with previous MI, and the
proportion of this population with a history of MI who
will have developed heart failure. We have applied these
proportions to a hypothetical practice population of
10,000 people to estimate the number who would have
had an MI and be in heart failure.
We have applied the Relative Risk Reduction (RRR) asso-
ciated with the use of the different drugs recommended by
the NICE guidelines from the results of randomised con-
trolled trials of drug treatment after acute MI and appro-
priate summaries of these trials. We have used 1-year RRR
where published, otherwise we have assumed that, de-
spite different follow-up periods for many of the trials, the
published RRR applies to 1-year mortality as well. We
have assumed that the same RRR applies to those with re-
cent MI (incident cases) and to those with a more remote
history of MI (prevalent cases). The RRR does appear to be
quite stable between trials and sub-groups within trials,
and in general does not vary with baseline risk [2].
We have estimated the baseline risk of mortality in the
next year among patients with a history of MI from an
Australian community register of mortality among pa-
tients discharged alive from hospital following an MI. We
used this register as data on mortality among prevalent
cases and from UK general practices are currently scarce.
We have confirmed the similarity of these data with infor-
mation from hospital registers in Scotland.
We have calculated the costs of commonly used drugs
over a one-year period (from MIMS) and have averaged
costs where two common formulations are available. We
chose dose levels that are likely to reflect typical clinical
practice. However, we have not included the investiga-
tions recommended by NICE (renal function for ACE-I
and serum potassium for spironolactone or the cost of
starting Beta Blockers in hospital), since although NICE
recommends this it is an unlikely sole reason for hospital
admission. We acknowledge that our estimates of costs
are crude and ignore the time spent by health profession-
als and all the other costs associated with the use of these
drugs both by the patient and the health care system.
For simplicity, we have assumed independence of the ef-
fect of the drugs (this has been demonstrated at least for
ACE-I [3] and aspirin [4]), and have examined their im-
pact individually, although an alternative method of han-
dling cumulative risk reduction with the use of multiple
drugs has been described [5] and could be applied. We
have added the impact of ACE-I and BB among those with
heart failure to the benefit from these drugs on the under-
lying MI, although this will tend to over-estimate the
benefits.
The measures used
We have used the established number need to treat (NNT)
and two recent measures for describing the population
impact of interventions. These are defined as follows, and
their formulae are shown as Table 1:
Number needed to treat (NNT) "the number of patients
who need to be treated to prevent one event" [6]
Disease Impact Number (DIN) "the number of those with
the disease in question amongst whom one event will be
prevented by the intervention"[7,8]
Population Impact Number (PIN) "the number of those
in the whole population amongst whom one event will be
prevented by the intervention" [7,8]
We now introduce two further definitions to allow the im-
pact to be related to the population of interest, such as a
general practice population.
Number to be Treated in your Population (NTP) "the
number of people in your population who will be eligible
for the treatment" and Number of Events Prevented in
your Population (NEPP) "the number of events prevented
by the intervention in your population" (see Table 1).
Cost is expressed as total drug cost for the intervention,
which provides an indication of the price the general prac-
tice or primary care organisation will have to pay for intro-
ducing this guideline. We also present the cost per death
prevented.
We assume a practice size of 10,000 people, amongst
whom there will be approximately 3,500 people aged 50BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/7
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or more to whom these interventions will be mainly rele-
vant and on whom the calculations are based. Table 2
shows the data and assumptions used for the calculations.
The proportion of a practice population with a history of
MI has been estimated from the Health Survey for Eng-
land 1998 [9] and we have calculated a weighted mean
proportion among men and women aged 50 or more. We
have estimated that 11% of patients with MI develop
heart failure based on co-morbidities coded in a popula-
tion register [10], consistent with prevalence data from
UK general practice [11].
The proportions of patients eligible for treatment with the
various drugs are taken from a recent systematic review
based on a variety of recommendations [12], adjusted for
those who may have clinical contraindications to use of
the drug.
The current proportions of patients who will already be
taking these drugs (to allow us to calculate incremental
needs) come from a systematic review of primary care
management of MI in general practice [12]. Similar data
for current heart failure treatment come from a UK Gener-
al Practice survey [11] for ACE-I and an Australian register
[10] for spironolactone. The baseline risk of death over
the next year among those discharged alive from hospital
has been taken from an Australian community register
[10]. These Australian data are very similar to 1-year death
rates from Scottish hospital data (if the Scottish 30-day
death rates are assumed to reflect in-hospital deaths and
are 'subtracted' from 1-year death rates to reflect rates
among those discharged to primary care) [13,14].
Results
Tables 3 and 4 show the calculations of the previously de-
scribed measures NNT, DIN and PIN as well as the
Number to be Treated in the Population (NTP) and the
Number of Events Prevented in the Population (NEPP).
Drug costs are presented as the total drug bill per year and
cost per death prevented in the population. The two tables
show the results assuming the total benefit of the drugs
and the incremental cost allowing for the fact that a
number of patients are already being treated with these
drugs. Using ACE-I as an example, 69 people will have to
be treated to prevent one death (NNT), although because
not all who have had an MI will be eligible for treatment
one death will be prevented by ACE-I amongst 93 people
post-MI (DIN). Use of ACE-I will prevent one death
among 1653 people aged 50+ in the practice (PIN). For
our notional practice population, this will require treating
147 patients for a year (NTP) and will prevent 2.12 deaths
(NEPP) at a total drug cost of €14,700 and a drug cost of
€6,944 per death prevented. The added benefit from ACE-
I among those with heart failure can be seen from Table 2.
Implementation of the NICE guidelines for the secondary
prevention of myocardial infarction (MI) will require 176
patients to be treated with aspirin, 147 patients with beta
blockers and with ACE-I and 157 patients with statins
(NTP). The benefit expressed as NEPP will range from
1.91 to 2.96 deaths prevented per year for aspirin and stat-
ins respectively. The drug cost per year to a General Prac-
tice varies from €1940 for aspirin to €60,525 for statins.
For those with heart failure after an MI, 16 patients would
be treated with ACE-Inhibitors, beta blockers and
spironolactone, and the benefit to a General Practice var-
ies from 0.96 to 1.37 of a death prevented per year for beta
blockers and spironolactone respectively at drug costs of
€709 and €2268. Assuming incremental costs only
(above those who are already on treatment), aspirin post
MI will be added for 37 patients and produce 0.40 of a
death prevented per year at a drug cost of €410 and statins
will be added for 120 patients and prevent 2.26 deaths per
year at a drug cost of €46,150.
Discussion
The methods we have presented would allow a primary
care organisation to assess the benefit and cost to them of
increasing their use of drugs to meet targets for secondary
prevention for CHD. The measures we have proposed are
easy to compute (provided the data exist). We believe that
the Number to be Treated in your Population (NTP) and
the Number of Events Prevented in your Population
Table 1: Definition of measures
Number needed to treat (NNT) "the number of patients who need to be treated to prevent one event" [6] = 1/(Baseline risk * RRR)
Disease Impact Number (DIN) "the number of those with the disease in question amongst whom one event will be prevented by the intervention" 
[7,8] = NNT * 1/Pe where Pe is the proportion of the diseased population eligible for treatment or; DIN = 1/(baseline risk * RRR * Pe)
Population Impact Number (PIN) "the number of those in the whole population amongst whom one event will be prevented by the intervention" [7,8] 
= DIN * 1/ Pd where Pd is the proportion of the population with the disease or; PIN = 1/(baseline risk * RRR * Pe * Pd)
Number to be Treated in your Population (NTP) "the number of people in your population who will be eligible for the treatment" = Population size 
* Pe * Pd
Number of Events Prevented in your Population (NEPP) "the number of events prevented by the intervention in your population" = Population size * 
Pe * Pd * Baseline risk * RRR (This can also be expressed as: NTP * Baseline risk * RRR; or; NTP * 1/NNT; or Population size/PIN).BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/7
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(NEPP), will provide useful measures of the population
impact of a wide range of interventions. They may be a
more meaningful measure for clinicians and health plan-
ners than the DIN and PIN from which they evolve [7,8].
Our work has highlighted the potential benefit of increas-
ing the low uptake of cardiovascular therapies in primary
care [20,21] and adds a potential method to help decide
which therapies might be used first.
There are, however, a number of potential factors that
would have to be taken into account by any primary care
organisation wishing to use these measures. The estimates
of benefit may well be over estimates as we have assumed
that all eligible patients are identified, treated and comply
with treatment. For example, Zermansky et al found that
only 44% of patients aged 65 or over with repeat
prescriptions had their medication reviewed [22]. The
costs are also under estimated by our restriction to drug
costs without taking into account additional staff and in-
formation system costs. Practice costs are likely to be de-
termined by other clinical decisions such as treatment of
patients with different clinical status and risk profiles –
the measures could be adapted to take account of these. In
addition, baseline risk estimates may very between prac-
tices in line with their age and socio-economic distribu-
tion as well as access to and quality of care.
The approach emphasises the importance of the collec-
tion of local data to develop an evidence base for popula-
tion health [8,23]. Whilst the RRR for drug treatment and
baseline risk of mortality or adverse events will usually be
derived from the literature, we see that to allow accurate
estimates of all the variables local data on baseline risk,
incidence and prevalence of the conditions and current
rates of prescribing are essential. The incremental drug
costs we have estimated will depend on current levels of
treatment in a practice. This is likely to vary according to
the enthusiasm with which a practice has already imple-
mented secondary prevention guidelines and may well
differ from the published data we have used as a basis for
our calculations. Local policies such as the use of statins at
older ages will also influence the findings, as will the de-
Table 2: Figures and assumptions used for the calculations.
MI MI + CHF
Proportion of practice population of 10,000 .056 [9] .006 [10,11]






Proportion eligible for incremental treatment – (proportion cur-
rently on treatment)
ACE-I .27 (.48) .16 (.59)
BB .43 (.32) .43 (.32)
Aspirin .19 (.71) N/a
Statins .61 (.19) N/a
Spironolactone N/a .55 (.20)
Baseline risk of death in the next year expressed as a proportion .09 [10] .29 [10]
RRR from trials.
ACE-I .16 [15] .15 [3]
BB .23 [16] .21 [17]
Aspirin .12 [4] N/a
Statins .21 [18] N/a
Spironolactone N/a .30 [19]
Costs (from MIMS, 2001)
ACE-I (Ramipril 2.5 mg @ €7.51/28; 
Lisinopril 10 mg @9.70/28)
€100 per year €100 per year
BB (Atenolol 25 mg @ €4.40/28; 
Metoprolol 100 mg @€6.68/56)
€45 per year €45 per year
Spironolactone 100 mg @ €39.50/100 €144 per year
Aspirin @ 94p/28 €11 per year
Statins (Simvastatin 20 mg or Pravastatin 
20 mg@ €29.69/28)
€386 per yearBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/7
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mographic and casemix composition of the practice pop-
ulation. We recommend that primary care organisations
should make these calculations, using their own preva-
lence estimates and local drug costs.
The drug costs we have calculated are indicative only, as
they will depend on the actual drug and dose chosen and
may vary over time and between organisations due to lo-
cally negotiated prices. Baseline risk would be expected to
be lower for prevalent than for incident cases, and we ac-
knowledge that our use of baseline risk, as well as of the
Relative Risk Reductions, derived from data in patients
with recent events will overestimate the benefits and cost-
effectiveness of treatment.
The calculation of the NNT from systematic reviews has
been criticised as the baseline risk to which the relative
risk reduction is applied is so variable between trials. Our
population impact measures are best applied using base-
line risks derived from local data (if available) to avoid
this criticism. It has been suggested that population im-
pact numbers are likely to be more variable than the NNT
or the Relative Risk Reduction [24], although this can be
accommodated by appropriate sensitivity analyses.
The confidence limits of these figures can be calculated
[8], however we recommend that sensitivity analyses be
performed to allow for differences in the estimates of each
variable [8]. We have only estimated the benefit of the
drugs in terms of mortality reductions and have not esti-
mated other outcomes such as events prevented, quality
of life or the harm of the drugs.
We believe that estimating the workload and population
impact of an intervention using NTP and NEPP is comple-
mentary to and often more useful than comparing cost per
Table 3: Benefits and drug costs over 1-year for a practice population of 10,000 resulting from the introduction of these treatments 









Number to be 
Treated in your 
Population 
(NTP)










ACE-I 69 93 1,653 147 2.12 14,700 6,944
BB 48 64 1,150 147 3.04 6,615 2,174
Statin 53 66 1,181 157 2.96 60,525 20,423
Aspirin 93 103 1,837 176 1.91 1,940 1,019
MI + CHF
ACE-I 23 31 5,109 16 0.69 1,575 2,299
BB 16 22 3,649 16 0.96 709 739
Spironolactone 11 15 2,554 16 1.37 2,268 1,655
MI myocardial Infarction CHF Heart Failure ACE-I ACE Inhibitor BB beta blocker
Table 4: Benefits and drug costs over 1-year to a practice population of 10,000 resulting from the introduction of these treatments 
assuming the incremental benefit of the drugs
Number Needed 
to Treat (NNT)
Number to be 
Treated in your 
Population (NTP)
Number of Events 
Prevented in your 
Population (NEPP)
Total drug cost (€) Drug cost per death 
prevented (€)
MI
ACE-I 69 53 0.76 5,292 6,944
BB 48 84 1.74 3,793 2,174
Statin 53 120 2.26 46,150 20,423
Aspirin 93 37 0.40 410 1,019
MI + CHF
ACE-I 23 3 0.15 336 2,299
BB 16 9 0.55 406 739
Spironolactone 11 12 1.00 1,663 1,655
MI myocardial Infarction CHF Heart Failure ACE-I ACE Inhibitor BB beta blockerBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/7
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death prevented. Cost-effectiveness estimates are heavily
influenced by the approach and underlying assumptions
and will change as drug (and other) costs change over
time, whereas baseline risk and RRR are less susceptible to
change.
Our measures will draw attention to the importance of
taking into account population impact in the decision
making process and hence may help a primary care organ-
isation to prioritise its approach to meet targets for CHD
and to choose between different targets to be met in pri-
mary care. We acknowledge that using the method to in-
form choices between primary and secondary prevention
through drug treatments and non-pharamacological in-
terventions is more complex, as is decision-making be-
tween preventive efforts for different diseases and
conditions. However, a modelling exercise has been per-
formed for primary prevention in general practice, and
again has found that the use of statins is more expensive
than other interventions for the potential amount of risk
reduction achieved [25].
Along similar lines, while smokers might benefit from the
use of cardiovascular prevention drugs, similar or greater
benefits might be obtained by cessation. Further work
with these measures, which we are planning, taking ac-
count of the potential of non-pharmacological interven-
tions would allow a comparison to be made. It would also
be important to include a comparison between interven-
tions aimed at different disease outcomes for priority set-
ting. Outcomes which include quality of life could also be
examined rather than concentrating on deaths prevented,
and methods for incorporating utilities into these meas-
ures would be welcome.
Conclusions
Despite some limitations, these measures have the advan-
tage of drawing attention to and quantifying the popula-
tion impact of alternative interventions. This should help
inform decision making, which generally occurs in the ab-
sence of explicit quantitative estimates of population
impact.
The actual estimates presented here should be regarded as
indicative only as further development of the measures,
and their application to local data are needed. Before that,
the estimates we have presented should be used with cau-
tion, although they should improve on other, less evi-
dence based methods to help a primary care organisation
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